Search results for: Institute for Clinical and Economic Review (ICER)
Filter search results
New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options
1 April 2011
…used for orphan drugs. An alternative might be upfront payment for registration (rather than for volume of use) in the form of an advance market commitment ‘prize’, a priority review…
New Drugs to Tackle Antimicrobial Resistance: EU Policy Options
1 October 2010
…policy discussions. The paper reviews AMR’s implications for the burden of disease, the causes of AMR, the current state of the antibiotic development pipeline and the reasons antibiotic R&D has…
Assessment and Appraisal of Oncology Medicines: NICE’s Approach and International HTA Experience
1 February 2009
…the need for better integration of social value judgments in the deliberative process, and the important differences among licensing agencies, HTA bodies and companies about how best to measure effectiveness….
Shalu Jain
29 June 2023
…social issues. She has an extensive experience of over 15 years in evidence synthesis, systematic reviews, meta-analysis, economic evaluations, HTA studies, and policy-level research. Dr Shalu has provided consulting and…
Lotte Steuten
8 January 2019
…research interests include applied health economics, health policy and market access. She specializes in quantitative methods for estimating and comparing the expected health and economic benefits of new interventions across…
After the Transplant: Potential Benefits for the NHS and UK Kidney Transplant Patients
1 November 2021
…care for patients, the NHS, and wider society, OHE, working on behalf of Novartis, developed an economic model that considers different aspects of transplant care. This model included information on…
Preventing Bronchitis
1 April 1977
…respiratory disorder, in particular cigarette smoking. It also describes the progressive nature of bronchitis, its causes and its social and economic costs and reviews the techniques employed in its treatment….
The Importance of Diversity of Supply in Rare Diseases Markets
23 January 2025
…and later commercialisation of medicines for rare diseases (RDs) are well known. While policies and incentives have been introduced at regulatory and reimbursement levels to address these challenges, markets for…
Pharmaceutical Innovation: Recent Trends, Future Prospects
1 October 1983
…blockers for angina and hypertension, the anxiolytics and antidepressants for psychiatric morbidity, preparations for common skin complaints and chemotherapy for gout. Concomitantly, pharmacological advance has played what might be viewed…